FDA Approved: ERIVEDGE — Supplemental Application (Genentech, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for ERIVEDGE (vismodegib) from Genentech, Inc. to modify or expand its labeling for basal cell carcinoma indications…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Basal Cell Carcinoma

Drugs mentioned

• Erivedge (vismodegib)

Snippet

SUPPL AP for ERIVEDGE (VISMODEGIB)